Biltmore Family Office LLC Buys 3,408 Shares of AbbVie Inc. $ABBV

Biltmore Family Office LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 10.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,925 shares of the company’s stock after buying an additional 3,408 shares during the quarter. AbbVie makes up 1.2% of Biltmore Family Office LLC’s portfolio, making the stock its 12th biggest holding. Biltmore Family Office LLC’s holdings in AbbVie were worth $8,086,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC bought a new position in AbbVie in the 2nd quarter worth $39,000. Finally, Bear Mountain Capital Inc. boosted its holdings in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV stock opened at $219.21 on Friday. The firm has a market cap of $387.42 billion, a PE ratio of 166.07, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36. The firm has a fifty day moving average price of $225.60 and a 200 day moving average price of $217.41. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Ratings Changes

Several equities analysts have recently commented on ABBV shares. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Morgan Stanley boosted their price target on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Scotiabank initiated coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Finally, Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.